NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO receives approval for Chlorantraniliprole (CTPR)- 1st key product of Crop Health Sciences Division05-02-2021
05-02-2021
NATCO PHARMA LTD. - 524816 - Closure of Trading Window
Please further note that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time TRADING WINDOW for dealing in the securities of the Company by the Employee(s) and their immediate relatives will be closed from 4th February, 2021 to 13th February, 2021 (both days inclusive). Trading window will be re-opened on 15th February 202103-02-2021
NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Consider The Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2020 And Consider 3Rd Interim Dividend, If Any
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2021 ,inter alia, to consider and approve the Unaudited Financial Results for the quarter and nine months ended 31st December, 2020 and consider 3rd Interim dividend, if any03-02-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 104695 equity shares of Rs.2/- each to the eligible employees of the company under NATSOP2017 scheme29-01-2021
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation oflssue of Duplicate Share Certificates08-01-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 46,795 Equity shares of Rs.2/- each ESOP under NATSOP2016 scheme04-01-2021
NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg 74(5) of SEBI (DP) Regulations, 201804-01-2021
NATCO PHARMA LTD. - 524816 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- M ADINARAYANADesignation :- Company Secretary and Compliance Officer04-01-2021
NATCO PHARMA LTD. - 524816 - Shareholding for the Period Ended December 31, 2020
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here04-01-2021